| Colorectal Carcinoma
Vectibix vs Yervoy
Side-by-side clinical, coverage, and cost comparison for colorectal carcinoma.Deep comparison between: Vectibix vs Yervoy with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsYervoy has a higher rate of injection site reactions vs Vectibix based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Yervoy but not Vectibix, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Vectibix
Yervoy
At A Glance
IV infusion
Every 2 weeks
EGFR antagonist
IV infusion
Every 3 weeks (monotherapy) or every 6 weeks (combination)
CTLA-4 antagonist
Indications
- Colorectal Carcinoma
- melanoma
- Renal Cell Carcinoma
- Colorectal Carcinoma
- Liver carcinoma
- Non-Small Cell Lung Carcinoma
- Malignant Pleural Mesothelioma
- Squamous cell carcinoma of esophagus
Dosing
Colorectal Carcinoma (RAS Wild-Type mCRC) 6 mg/kg IV infusion every 14 days over 60 minutes (<=1000 mg) or 90 minutes (>1000 mg) as monotherapy or in combination with FOLFOX.
Colorectal Carcinoma (KRAS G12C-Mutated mCRC) 6 mg/kg IV infusion every 14 days over 60 minutes (<=1000 mg) or 90 minutes (>1000 mg) in combination with sotorasib; administer first sotorasib dose prior to first Vectibix infusion.
Melanoma (unresectable or metastatic) 3 mg/kg IV every 3 weeks for 4 doses, or 3 mg/kg IV with nivolumab 1 mg/kg IV every 3 weeks for 4 doses followed by nivolumab monotherapy
Melanoma (adjuvant) 3 mg/kg IV every 3 weeks for 4 doses, then 3 mg/kg every 12 weeks for up to 4 additional doses
Renal Cell Carcinoma 1 mg/kg IV with nivolumab 3 mg/kg IV every 3 weeks for 4 doses, followed by nivolumab monotherapy
Colorectal Carcinoma 1 mg/kg IV with nivolumab 240 mg or 3 mg/kg IV (weight-based) every 3 weeks for 4 doses, followed by nivolumab monotherapy
Liver carcinoma 3 mg/kg IV with nivolumab 1 mg/kg IV every 3 weeks for up to 4 doses, followed by nivolumab monotherapy
Non-Small Cell Lung Carcinoma 1 mg/kg IV every 6 weeks with nivolumab 360 mg every 3 weeks, or with nivolumab and 2 cycles of platinum-doublet chemotherapy
Malignant Pleural Mesothelioma 1 mg/kg IV every 6 weeks with nivolumab 360 mg every 3 weeks
Squamous cell carcinoma of esophagus 1 mg/kg IV every 6 weeks with nivolumab 3 mg/kg every 2 weeks or 360 mg every 3 weeks
Contraindications
—
—
Adverse Reactions
Most common (>=20%) Rash, acneiform dermatitis, erythema, pruritus, dry skin, paronychia, diarrhea, stomatitis, mucosal inflammation, fatigue, asthenia, nausea, anorexia, hypomagnesemia, hypokalemia, musculoskeletal pain
Serious General physical health deterioration, intestinal obstruction, diarrhea, dehydration, sepsis, cardiac arrest
Postmarketing Skin necrosis, angioedema, bullous mucocutaneous disease, infusion reaction, keratitis, ulcerative keratitis, corneal perforation
Most common (>=20%) fatigue, diarrhea, rash, pruritus, nausea, pyrexia, musculoskeletal pain, decreased appetite, cough, headache, dyspnea, vomiting, abdominal pain, arthralgia
Serious immune-mediated colitis, hepatitis, pneumonitis, endocrinopathies, nephritis, dermatologic reactions, neurological toxicities, myocarditis, adrenal insufficiency, hypophysitis, hyperthyroidism, hypothyroidism
Pharmacology
Panitumumab is a fully human IgG2 monoclonal antibody that competitively blocks ligand binding to EGFR, inhibiting receptor autophosphorylation and downstream signaling, thereby inhibiting tumor cell growth and inducing apoptosis; in KRAS G12C-mutated mCRC, combining EGFR blockade with sotorasib overcomes EGFR-mediated resistance to KRAS G12C inhibition.
Ipilimumab blocks CTLA-4, a negative regulator of T-cell activity, thereby augmenting T-cell activation and proliferation including tumor-infiltrating T-effector cells and reducing T-regulatory cell function.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Vectibix
- Covered on 5 commercial plans
- PA (12/12) · Step Therapy (0/12) · Qty limit (0/12)
Yervoy
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (0/12) · Qty limit (0/12)
UnitedHealthcare
Vectibix
- Covered on 4 commercial plans
- PA (3/8) · Step Therapy (3/8) · Qty limit (0/8)
Yervoy
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Vectibix
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (0/3)
Yervoy
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAmgen Safety Net Foundation
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
No savings programs available for Yervoy.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
VectibixView full Vectibix profile
YervoyView full Yervoy profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.